Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Cardiovascular and Renal Effectiveness and Safety of Empagliflozin and Other SGLT2i in Patients With Type 2 Diabetes (T2D) With and Without Baseline Kidney Disease in the United States

Next Previous
Trial Profile

Comparative Cardiovascular and Renal Effectiveness and Safety of Empagliflozin and Other SGLT2i in Patients With Type 2 Diabetes (T2D) With and Without Baseline Kidney Disease in the United States

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide-1 receptor agonists; Sodium-glucose transporter 2 inhibitors
  • Indications Cardiovascular disorders; Renal failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 11 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 19 Sep 2022 Planned End Date changed from 17 Sep 2022 to 30 Sep 2022.
  • 19 Sep 2022 Planned primary completion date changed from 17 Sep 2022 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top